Current status of anti-angiogenesis therapy for prostate cancer{star, open}

Juan Antonio Jiménez, Chinghai Kao, Sudhanshu Raikwar, Thomas Gardner

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.

Original languageEnglish
Pages (from-to)260-268
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number3
DOIs
StatePublished - May 2006

Fingerprint

Prostatic Neoplasms
Therapeutics
Neoplasms
Neoplasm Metastasis
Mortality
Growth

Keywords

  • Adenovirus
  • Anti-angiogenesis
  • Gene therapy
  • Prostate cancer
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Current status of anti-angiogenesis therapy for prostate cancer{star, open}. / Jiménez, Juan Antonio; Kao, Chinghai; Raikwar, Sudhanshu; Gardner, Thomas.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 24, No. 3, 05.2006, p. 260-268.

Research output: Contribution to journalArticle

@article{d67a8eec23354b0891982ebaf4d3e069,
title = "Current status of anti-angiogenesis therapy for prostate cancer{star, open}",
abstract = "Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.",
keywords = "Adenovirus, Anti-angiogenesis, Gene therapy, Prostate cancer, Vascular endothelial growth factor",
author = "Jim{\'e}nez, {Juan Antonio} and Chinghai Kao and Sudhanshu Raikwar and Thomas Gardner",
year = "2006",
month = "5",
doi = "10.1016/j.urolonc.2005.11.022",
language = "English",
volume = "24",
pages = "260--268",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Current status of anti-angiogenesis therapy for prostate cancer{star, open}

AU - Jiménez, Juan Antonio

AU - Kao, Chinghai

AU - Raikwar, Sudhanshu

AU - Gardner, Thomas

PY - 2006/5

Y1 - 2006/5

N2 - Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.

AB - Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.

KW - Adenovirus

KW - Anti-angiogenesis

KW - Gene therapy

KW - Prostate cancer

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33646205440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646205440&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.11.022

DO - 10.1016/j.urolonc.2005.11.022

M3 - Article

VL - 24

SP - 260

EP - 268

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -